Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where F. Schillo is active.

Publication


Featured researches published by F. Schillo.


Endocrine-related Cancer | 2015

Pituitary MRI characteristics in 297 acromegaly patients based on T2-weighted sequences

Iulia Potorac; Patrick Petrossians; Adrian Daly; F. Schillo; Claude Ben Slama; Sonia Nagi; Mouna Sahnoun; Thierry Brue; Nadine Girard; Philippe Chanson; Ghaidaa Nasser; Philippe Caron; Fabrice Bonneville; Gérald Raverot; V. Lapras; François Cotton; B. Delemer; Brigitte Higel; Anne Boulin; Stephan Gaillard; Florina Luca; Bernard Goichot; Jean-Louis Dietemann; Albert Beckers; Jean-François Bonneville

Responses of GH-secreting adenomas to multimodal management of acromegaly vary widely between patients. Understanding the behavioral patterns of GH-secreting adenomas by identifying factors predictive of their evolution is a research priority. The aim of this study was to clarify the relationship between the T2-weighted adenoma signal on diagnostic magnetic resonance imaging (MRI) in acromegaly and clinical and biological features at diagnosis. An international, multicenter, retrospective analysis was performed using a large population of 297 acromegalic patients recently diagnosed with available diagnostic MRI evaluations. The study was conducted at ten endocrine tertiary referral centers. Clinical and biochemical characteristics, and MRI signal findings were evaluated. T2-hypointense adenomas represented 52.9% of the series, were smaller than their T2-hyperintense and isointense counterparts (P<0.0001), were associated with higher IGF1 levels (P=0.0001), invaded the cavernous sinus less frequently (P=0.0002), and rarely caused optic chiasm compression (P<0.0001). Acromegalic men tended to be younger at diagnosis than women (P=0.067) and presented higher IGF1 values (P=0.01). Although in total, adenomas had a predominantly inferior extension in 45.8% of cases, in men this was more frequent (P<0.0001), whereas in women optic chiasm compression of macroadenomas occurred more often (P=0.0067). Most adenomas (45.1%) measured between 11 and 20 mm in maximal diameter and bigger adenomas were diagnosed at younger ages (P=0.0001). The T2-weighted signal differentiates GH-secreting adenomas into subgroups with particular behaviors. This raises the question of whether the T2-weighted signal could represent a factor in the classification of acromegalic patients in future studies.


Endocrine-related Cancer | 2016

T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly.

Iulia Potorac; Patrick Petrossians; Adrian Daly; Orsalia Alexopoulou; Sophie Borot; Mona Sahnoun-Fathallah; Frederic Castinetti; Marie Lise Jaffrain-Rea; Claire Briet; Florina Luca; Marion Lapoirie; Flavius Zoicas; I. Simoneau; Alpha Mamadou Diallo; Ammar Muhammad; Fahrettin Kelestimur; Elena Nazzari; Rogelio Garcia Centeno; Susan M. Webb; Marie Laure Nunes; Vaclav Hana; Véronique Pascal-Vigneron; Irena Ilovayskaya; Farida Nasybullina; Samia Achir; Diego Ferone; Sebastian Neggers; B. Delemer; Jean Michel Petit; Christof Schöfl

GH-secreting pituitary adenomas can be hypo-, iso- or hyper-intense on T2-weighted MRI sequences. We conducted the current multicenter study in a large population of patients with acromegaly to analyze the relationship between T2-weighted signal intensity on diagnostic MRI and hormonal and tumoral responses to somatostatin analogs (SSA) as primary monotherapy. Acromegaly patients receiving primary SSA for at least 3 months were included in the study. Hormonal, clinical and general MRI assessments were performed and assessed centrally. We included 120 patients with acromegaly. At diagnosis, 84, 17 and 19 tumors were T2-hypo-, iso- and hyper-intense, respectively. SSA treatment duration, cumulative and mean monthly doses were similar in the three groups. Patients with T2-hypo-intense adenomas had median SSA-induced decreases in GH and IGF-1 of 88% and 59% respectively, which were significantly greater than the decreases observed in the T2-iso- and hyper-intense groups (P < 0.001). Tumor shrinkage on SSA was also significantly greater in the T2-hypo-intense group (38%) compared with the T2-iso- and hyper-intense groups (8% and 3%, respectively; P < 0.0001). The response to SSA correlated with the calculated T2 intensity: the lower the T2-weighted intensity, the greater the decrease in random GH (P < 0.0001, r = 0.22), IGF-1 (P < 0.0001, r = 0.14) and adenoma volume (P < 0.0001, r = 0.33). The T2-weighted signal intensity of GH-secreting adenomas at diagnosis correlates with hormone reduction and tumor shrinkage in response to primary SSA treatment in acromegaly. This study supports its use as a generally available predictive tool at diagnosis that could help to guide subsequent treatment choices in acromegaly.


Investigational New Drugs | 2018

Long-term adverse event: inflammatory orbitopathy induced by pembrolizumab in a patient with metastatic melanoma

Charlée Nardin; Sophie Borot; Marie-Astride Beaudoin; Françoise Cattin; E. Puzenat; Anne-Sophie Gauthier; F. Schillo; Christophe Borg; F. Aubin

SummaryThe recent advent of immune checkpoint inhibitors (ICI), including anti-programmed cell death 1 protein (anti-PD-1) agents has revolutionized the therapeutic approach of metastatic malignancies. Yet, ICI can disrupt immune tolerance resulting in enhanced immune activation in normal tissues with significant toxicity. A dysregulated activation of T-cells directed to normal tissues stands as the main mechanism of immune-related adverse events (irAE). To date, only two cases of immune-related inflammatory orbitopathy related to anti-PD-1 agents have been reported. This rare immune adverse event usually occurred early after ICI initiation. Here, we report the first case of late inflammatory orbitopathy occurring in a melanoma patient treated with pembrolizumab. Consequently, the occurrence of irAE under ICI should be monitored, even late after treatment instauration.


Diabetes & Metabolism | 2016

CA-095: Admission aux urgences pour hypoglycémie ou décompensation hyperglycémique chez les patients diabétiques : un passage obligé ?

A. Bazin; Lucie Meillet; F. Schillo; T. Desmettre; S. Borot

Resume Les consultations dans les services d’accueil d’urgence (SAU) pour hypoglycemie ou hyperglycemie chez les patients diabetiques, sont frequentes. Le temps d’attente est parfois long, et les patients sont souvent hospitalises dans des services non specialises pour la prise en charge de leur diabete. Le but de notre travail etait d’analyser, sur une annee, les venues aux urgences pour desequilibre du diabete, afin de voir s’il etait possible d’envisager une prise en charge alternative, en ambulatoire, ou en hospitalisation differee dans un service de diabetologie.


Feuillets De Radiologie | 2004

L’IRM après chirurgie transsphénoïdale

Jean Francois Bonneville; Fabrice Bonneville; F. Schillo; Françoise Cattin; Gabrielle A. Jacquet

Resume Les auteurs rapportent leur experience du suivi par IRM de plus de 250 adenomes hypophysaires operes par voie transsphenoidale. Dans tous les cas, les patients ont ete suivis par une IRM a J4, puis entre 2 et 3 mois, puis a 1 an et au-dela apres l’intervention. La reproductibilite des examens dans le temps est essentielle pour faire le diagnostic precoce de recidive de l’adenome hypophysaire.


Annales D Endocrinologie | 2013

Corrélations significatives de l’aspect en IRM Haute Résolution des adénomes hypophysaires à GH avant traitement

Iulia Potorac; Patrick Petrossians; F. Schillo; C. Ben Slama; S. Nagi; Mouna Sahnoun; Thierry Brue; Nadine Girard; Philippe Chanson; Ghaidaa Nasser; Philippe Caron; Fabrice Bonneville; Gérald Raverot; V. Lapras; François Cotton; B. Delemer; Brigitte Higel; Anne Boulin; Stephan Gaillard; Bernard Goichot; Jean-Louis Dietemann; J. Kreutz; Luaba Tshibanda; Albert Beckers; Jean-François Bonneville


Presse Medicale | 2017

Effets secondaires des inhibiteurs de checkpoint utilisés dans le traitement des mélanomes et d’autres cancers

Claire Jacquin-Porretaz; Charlée Nardin; E. Puzenat; Blandine Roche-Kubler; F. Aubin; F. Schillo; Lucie Meillet; Sophie Borot; Lucine Vuitton; Stéphane Koch; Virginie Westeel; Pascale Jacoulet; Jean Paul Cervoni; Vincent Di Martino; Adrien Chauchet; Daniel Wendling; Marc Badoz; Didier Ducloux; Laurent Tatu; Bernard Delbosc


Archive | 2018

Evaluation de la mise sous pompe en ambulatoire au CHRU de Besançon.

Patricia Gilet; C. Kleinclauss; Lucie Meillet; Annie Clergeot; Marie-Astrid Beaudoin; Sylvie Grandperret; Cécile Zimmermann; F. Schillo; S. Borot


Annales D Endocrinologie | 2018

Une orbitopathie basedowienne corticorésistante à TRAb négatifs

M.A. Beaudoin; L. Meillet; F. Schillo; S. Borot


Annales D Endocrinologie | 2018

Lymphome intravasculaire et hypophyse : à propos d’un cas

M. Briet; S. Borot; F. Schillo; L. Meillet; S. Billet; P. Combaud

Collaboration


Dive into the F. Schillo's collaboration.

Top Co-Authors

Avatar

S. Borot

University of Franche-Comté

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Lucie Meillet

University of Franche-Comté

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Orsalia Alexopoulou

Université catholique de Louvain

View shared research outputs
Researchain Logo
Decentralizing Knowledge